Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
VIP
Also known as: Vasoactive Intestinal Peptide, Vasoactive Intestinal Polypeptide
VIP is an endogenous 28-amino acid neuropeptide with broad physiological roles including vasodilation, smooth muscle relaxation, immune modulation, and neuroprotection. It has been investigated in clinical settings for pulmonary hypertension, sarcoidosis, and chronic inflammatory response syndrome (CIRS). Dr. Ritchie Shoemaker popularized its use in CIRS/mold illness protocols.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 37221-79-7 |
| Molecular Formula | C147H237N43O44S |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Binds VPAC1 and VPAC2 receptors activating cAMP/PKA signaling. Causes vasodilation, bronchodilation, and inhibition of pro-inflammatory cytokines. Promotes regulatory T-cell differentiation, suppresses Th17 responses, and has neuroprotective effects via BDNF upregulation.
Dosing Research
CIRS protocol: 50 mcg intranasally 4 times daily, titrated based on labs (VIP levels, MSH, TGF-beta1). Clinical trial doses have ranged from 1-200 mcg intranasally. Must be compounded and stored properly as VIP is fragile.
Side Effects & Risks
Nasal congestion, rhinorrhea, and transient hypotension are common. Diarrhea can occur at higher doses. Should not be used with active mold exposure or elevated MARCoNS. Theoretical risk of promoting tumor growth in certain cancers due to angiogenic properties.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.